In our latest Ask an Ion, Evan shares a glimpse into his role as a senior research associate in Manufacturing & Operations at Ionis and answers one question you probably never thought to ask: what piece of manufacturing equipment would you be and why? Watch the video to see the unique perspective and sense of humor Evan brings to the work he does at Ionis. #IONIScareers
Ionis Pharmaceuticals, Inc.
Biotechnology Research
Carlsbad, CA 114,848 followers
Building on our impossible firsts, we can change the course of human health.
About us
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
- Website
-
http://www.ionis.com
External link for Ionis Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Carlsbad, CA
- Type
- Public Company
- Founded
- 1989
- Specialties
- RNA-targeted medicines and RNA-targeted therapeutics
Locations
-
Primary
Get directions
2855 Gazelle Ct
Carlsbad, CA 92010, US
Employees at Ionis Pharmaceuticals, Inc.
Updates
-
Save the date for our Q2 2026 earnings webcast. Register now and tune in live on July 29 at 8:30 am ET: https://bit.ly/4wDN85h
-
-
Today, our partner Biogen shared data at #AAIC26 from the Phase 2 CELIA study evaluating our investigational antisense oligonucleotide (ASO) therapy targeting tau in individuals with early Alzheimer’s disease. Read more: https://bit.ly/4f9Podu #AlzheimersDisease
-
-
Today, we announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating our investigational RNA-targeted medicine for people living with Dravet syndrome. Learn more: https://bit.ly/4aLyFfh #DravetSyndrome #Dravet
-
-
Today, we shared an update from our Phase 3 CARDIO-TTRansform study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Read more: https://bit.ly/4eUoCak
-
-
Today we announced that we’ve completed enrollment in the pivotal cohort of the global Phase 3 REVEAL study of our investigational RNA-targeted medicine for people living with Angelman syndrome. Read more: https://bit.ly/4p7Hztq #AngelmanSyndrome #Angelman
-
-
For people with very high #triglycerides 500 mg/dL or above – known as severe hypertriglyceridemia (#sHTG) – they remain vulnerable to unpredictable and potentially life-threatening acute pancreatitis attacks. We’re proud to deliver this new treatment for sHTG, which has the potential to make a meaningful difference to the sHTG community. Learn more: https://bit.ly/4anHdsz
-
-
Our medicine for severe hypertriglyceridemia (#sHTG) is now approved in the U.S., bringing an innovative solution to managing very high #triglycerides 500 mg/dL or above. Learn more about the unmet needs and importance of this milestone: https://bit.ly/4anHdsz
-
-
Today we announced we’ve entered into a license agreement with Recordati, granting them exclusive rights to develop and commercialize our investigational RNA-targeted medicine for Alexander disease in all countries outside the U.S. Read more: https://bit.ly/4gzvKde #AlexanderDisease
-
-
Today, the U.S. FDA approved our medicine for severe hypertriglyceridemia (#sHTG) to reduce triglycerides and the risk of acute pancreatitis – marking a historic advance in lipid management for patients. Hear from our CEO, Brett P. Monia, PhD.